Tuberculosis (TB) Clinical Trial
Official title:
Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.
This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine administered at 0, 1 months to healthy adults living in a TB-endemic region. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06272812 -
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.
|
Phase 2 | |
| Active, not recruiting |
NCT01875952 -
Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
|
Phase 4 | |
| Completed |
NCT03929705 -
Assessing the Ability of the T-SPOT®.TB Test
|
||
| Recruiting |
NCT03808636 -
Innovative Reagents for Improving Rapid Diagnosis of Mycobacterial Infections
|
||
| Completed |
NCT01879163 -
Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults
|
Phase 1 | |
| Completed |
NCT00146744 -
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults
|
Phase 2 | |
| Completed |
NCT00291889 -
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.
|
Phase 1 | |
| Recruiting |
NCT04333485 -
Tuberculosis (TB) Aftermath
|
N/A | |
| Completed |
NCT00730795 -
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults
|
Phase 1 | |
| Withdrawn |
NCT04243031 -
QuantiFERON Access Clinical Performance Study Protocol
|